Highlights
- •In the PFA–100® analyser, the shorter closure times (CT) are associated with an increased VTE risk.
- •Whole blood aggregation is not related to VTE risk.
- •Other mechanisms of platelet function, such as adhesion, must be involved in the pathogenesis of VTE.
Abstract
Introduction
Platelets play a role in the pathophysiology of venous thromboembolism (VTE). Some
studies have not found an association between VTE and platelet aggregation. The PFA–100®
analyser is an in vitro assay for assessing primary haemostasis. But, there are no studies to evaluate its
association with VTE. We investigated the contribution of the global platelet function
and aggregation in the development of VTE.
Material and methods
We analysed 800 individuals who were included in the RETROVE Study (Riesgo de Enfermedad
TROmboembólica VEnosa). Global platelet function was evaluated as closure times (CT)
with the agonists ADP and epinephrine using a PFA–100® analyser. Platelet aggregation
was evaluated by Multiplate™ analyser. The VTE risk for all the parameters was calculated
by unconditional logistic regression analyses considering the potential confounders:
age, gender, body mass index (BMI), factor VIII (FVIII), the von Willebrand factor
(vWF) and the ABO blood group system.
Results
The unadjusted odds ratio (OR) values ≤10th percentile for the PFAadp and PFAepi were 4.02 (95% CI, 2.76–5.95)
and 3.33 (2.27–4.97). Also, after adjusting for vWF, we obtained lower OR for the
PFAadp and for PFAepi: 2.24 (1.44–3.49) and 1.63 (1.04–2.59). But, the whole blood
aggregation parameters did not shown an association with VTE risk.
Conclusion
We demonstrated an association between short CT and VTE risk. Although, the whole
blood aggregation parameters did not show an association with the VTE risk. This striking
contrast suggests that there are other platelet function mechanisms (e.g. adhesion) that are responsible of VTE risk.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Thrombosis ResearchAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- A prospective study of the incidence of deep-vein thrombosis within a defined urban population.J. Intern. Med. 1992; 232: 155-160
- Genetic susceptibility to thrombosis and its relationship to physiological risk factors: the GAIT study. Genetic analysis of idiopathic thrombophilia.Am. J. Hum. Genet. 2000; 67: 1452-1459https://doi.org/10.1086/316903
- Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.J. Exp. Med. 2012; 209: 819-835https://doi.org/10.1084/jem.20112322
- Platelets at the interface of thrombosis, inflammation, and cancer.Blood. 2015; 126: 582-588https://doi.org/10.1182/blood-2014-08-531582
- Initiation of platelet adhesion by arrest onto fibrinogen or translocation on von Willebrand factor.Cell. 1996; 84: 289-297
- Importance of platelets in experimental venous thrombosis in the rat.Blood. 1992; 80: 2281-2286
- von Willebrand factor-mediated platelet adhesion is critical for deep vein thrombosis in mouse models.Blood. 2011; 117: 1400-1407https://doi.org/10.1182/blood-2010-05-287623
- Role of platelets, neutrophils, and factor XII in spontaneous venous thrombosis in mice.Blood. 2016; 127: 2630-2637https://doi.org/10.1182/blood-2015-10-672766
- The role of platelets in venous thromboembolism.Semin. Thromb. Hemost. 2016; 42: 242-251https://doi.org/10.1055/s-0035-1570079
- Laboratory testing for platelet function disorders.Int. J. Lab. Hematol. 2015; 37: 18-24https://doi.org/10.1111/ijlh.12346
- Platelet function tests: a comparative review.Vasc. Health Risk Manag. 2015; 11: 133-148https://doi.org/10.2147/VHRM.S44469
- Platelet function analyzer (PFA-100): a tool to quantify congenital or acquired platelet dysfunction.J. Lab. Clin. Med. 2001; 138: 152-163
- Clinical utility of the PFA-100.Semin. Thromb. Hemost. 2008; 34: 709-733https://doi.org/10.1055/s-0029-1145254
- Assessment of platelet function on whole blood by multiple electrode aggregometry in high-risk patients with coronary artery disease receiving antiplatelet therapy.Am. J. Clin. Pathol. 2009; 131: 834-842https://doi.org/10.1309/AJCPTE3K1SGAPOIZ
- Methodological considerations for the assessment of ADP induced platelet aggregation using the Multiplate® analyser.Platelets. 2013; 24: 303-307https://doi.org/10.3109/09537104.2012.694086
- Multiple electrode aggregometry: a new device to measure platelet aggregation in whole blood.Thromb. Haemost. 2006; 96: 781-788https://doi.org/10.1160/TH06-05-0242
- A predictive model of high shear thrombus growth.Ann. Biomed. Eng. 2016; : 1-12https://doi.org/10.1007/s10439-016-1550-5
- Platelet function as a risk factor for venous thromboembolism in the Framingham Heart Study.Thromb. Res. 2017; 151: 57-62https://doi.org/10.1016/j.thromres.2017.01.010
- Decreased threshold of aggregation to low-dose epinephrine is evidence of platelet hyperaggregability in patients with thrombosis.Hematol. Rep. 2014; 65326https://doi.org/10.4081/hr.2014.5326
- Epidemiology of first and recurrent venous thromboembolism: a population-based cohort study in patients without active cancer.Thromb. Haemost. 2014; 112: 255-263https://doi.org/10.1160/TH13-09-0793
- Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH.J. Thromb. Haemost. 2016; 14: 1480-1483https://doi.org/10.1111/jth.13336
- A simple salting out procedure for extracting DNA from human nucleated cells.Nucleic Acids Res. 1988; 16: 1215
- Functional effects of the ABO locus polymorphism on plasma levels of von Willebrand factor, factor VIII, and activated partial thromboplastin time.Arterioscler. Thromb. Vasc. Biol. 2000; 20: 2024-2028
- Venous and arterial thrombosis: two aspects of the same disease?.Eur. J. Intern. Med. 2009; 20: 660-661https://doi.org/10.1016/j.ejim.2009.02.001
- Risk factors for venous and arterial thrombosis.Blood Transfus. 2011; 9: 120-138https://doi.org/10.2450/2010.0066-10
- Metric predicted variable with multiple nominal predictors.in: Doing Bayesian Data Anal. 2n. ed. Academic Press, London2015: 583-620
- The ABO blood group genotype and factor VIII levels as independent risk factors for venous thromboembolism.Thromb. Haemost. 2005; 93: 468-474https://doi.org/10.1160/TH04-04-0251
- ABO blood group genotypes and the risk of venous thrombosis: effect of factor V Leiden.J. Thromb. Haemost. 2005; 3: 183-185https://doi.org/10.1111/j.1538-7836.2004.01071.x
- Age and gender effects on 15 platelet phenotypes in a Spanish population.Comput. Biol. Med. 2016; 69: 226-233https://doi.org/10.1016/j.compbiomed.2015.12.023
- Role of von Willebrand factor in the haemostasis.Blood Transfus. 2011; 9: s3-s8https://doi.org/10.2450/2011.002S
- Elevated factor VIII levels and the risk of thrombosis.Arterioscler. Thromb. Vasc. Biol. 2001; 21: 731-738https://doi.org/10.1161/01.ATV.21.5.731
- Utility of the PFA-100 for assessing bleeding disorders and monitoring therapy: a review of analytical variables, benefits and limitations.Haemophilia. 2001; 7: 170-179
- Indices of platelet activation and the stability of coronary artery disease.J. Thromb. Haemost. 2007; 5: 761-765https://doi.org/10.1111/j.1538-7836.2007.02462.x
- Enhanced platelet aggregation with TRAP-6 and collagen in platelet aggregometry in patients with venous thromboembolism.Thromb. Res. 2002; 107: 325-328https://doi.org/10.1016/S0049-3848(02)00351-1
- Sticky platelet syndrome in patients with unexplained venous thrombosis.Turk. J. Hematol. 2011; 30: 48-52https://doi.org/10.5152/tjh.2011.79
- Aspirin for preventing the recurrence of venous thromboembolism.N. Engl. J. Med. 2012; 366: 1959-1967https://doi.org/10.1056/NEJMoa1114238
- Low-dose aspirin for preventing recurrent venous thromboembolism.N. Engl. J. Med. 2012; 367: 1979-1987https://doi.org/10.1056/NEJMoa1210384
- Rivaroxaban or aspirin for extended treatment of venous thromboembolism.N. Engl. J. Med. 2017; 376: 1211-1222https://doi.org/10.1056/NEJMoa1700518
Article info
Publication history
Published online: July 12, 2018
Accepted:
July 5,
2018
Received in revised form:
June 27,
2018
Received:
April 20,
2018
Identification
Copyright
© 2018 Elsevier Ltd. All rights reserved.
